CD274 and hepatocellular carcinoma: In September 2020, following the results of the IMbrave150 trial [41], atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, and in September 2020, the combination of atezolizumab, an PD-L1 antibody, and bevacizumab, a VEGF inhibitor, were approved and will become the first-line treatment for unresectable HCC by 2022.